2011 News | Events | Industry Updates
Selcia has successfully completed 14C radiolabelled API projects on behalf of a diverse range of clients for phase 1 human trials, following MHRA GMP Certification in September 2010.
Selcia are proud to announce the publication of the latest poster on our proprietary CEfrag™ fragment screening technology.
It is with great sadness that we report the loss of two friends, Jim Little and Bruce Lowery.
Selcia Limited and Swedish drug development company NeuroVive Pharmaceutical AB have signed a significant research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology
In response to an ever-growing US client base, Selcia today announced the opening of their new SelciaWest facility, in Hopkinton MA (USA).